Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO
about
Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?Dendritic cell-targeted approaches to modulate immune dysfunction in the tumor microenvironmentUtilizing the FIV model to understand dendritic cell dysfunction and the potential role of dendritic cell immunization in HIV infection.Haemophilus ducreyi lipooligosaccharides induce expression of the immunosuppressive enzyme indoleamine 2,3-dioxygenase via type I interferons and tumor necrosis factor alpha in human dendritic cells.Leukotriene C4 induces migration of human monocyte-derived dendritic cells without loss of immunostimulatory function.Dendritic cell-based cancer vaccination: quo vadis?The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells.Directing dendritic cell immunotherapy towards successful cancer treatment.The multiple faces of prostaglandin E2 G-protein coupled receptor signaling during the dendritic cell life cycle.Tumour-induced immune suppression: role of inflammatory mediators released by myelomonocytic cells.Detection of prostaglandin E2-induced dendritic cell migration into the lymph nodes of mice using a 1.5 T clinical MR scanner.Vascular endothelial growth factor-A enhances indoleamine 2,3-dioxygenase expression by dendritic cells and subsequently impacts lymphocyte proliferationAKAPs in lipid rafts are required for optimal antigen presentation by dendritic cells.The missing link between indoleamine 2,3-dioxygenase mediated antibacterial and immunoregulatory effects.Phenotypic and functional markers for 1alpha,25-dihydroxyvitamin D(3)-modified regulatory dendritic cells.Comparative study of dendritic cells matured by using IL-1β, IL-6, TNF-α and prostaglandins E2 for different time span.DC-ATLAS: a systems biology resource to dissect receptor specific signal transduction in dendritic cells.Indolamine 2,3-dioxygenase expression by monocytes and dendritic cell populations in hepatitis C patients.Preparation of tumor antigen-loaded mature dendritic cells for immunotherapy.Indoleamine-2,3-dioxygenase enzyme expression and activity in polarized dendritic cellsPGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response.Ambivalent effects of dendritic cells displaying prostaglandin E2-induced indoleamine 2,3-dioxygenase.Dendritic cell immunotherapy.CD137 stimulation and p38 MAPK inhibition improve reactivity in an in vitro model of glioblastoma immunotherapy.
P2860
Q26830857-1B9C6588-1F79-48B2-B7AB-9EDEA751F4FEQ27000318-E50C5159-CB4F-4BEB-B372-592A5C27E0F4Q33653728-4DA4FCD3-77AD-4AF3-8CFE-3B7D96E94F44Q35139241-ADD1877C-214E-4195-AA3D-BC5EFFBA451AQ35876990-78C69F63-037A-4FE7-9A1A-1971207161EEQ37259624-3CFCCA5C-0661-4D55-8E3F-B5ABB0FDE7C0Q37528354-6E69E33D-A8D9-4716-A254-AB463802A9C5Q37754014-443ADD72-CC2B-4CFC-905A-EB93941AF608Q38093015-AFCBE627-C58C-46FB-89D9-6D2FD1FB18A2Q38193589-9C9C54CC-2F57-4CAF-A8B4-D6421F9E0162Q38469509-F1B2BD10-E14B-40DE-A8C4-FCF775E4A74DQ39091474-0D50CAEC-2E61-4273-BB8A-5CE1870961C2Q39609537-E5DEDFCA-5C65-4BC3-A28C-7F61D3BFC4B8Q39825479-E597F0B3-B775-4451-9F8A-BB6C891B8C6FQ39957476-A1E020FA-F1A8-4FA9-BEE1-27817A0ABEE3Q40092538-94DE4D09-F6D4-4E9B-9BFA-809FEC572F14Q41127264-2F692140-7BDA-4E37-8625-644B5915BDD4Q41531461-648AD7CD-2114-469E-973C-3F2C1BC0AE69Q41855097-DDA75E87-107E-4937-9F4E-C56C30B28CF7Q42108021-97901DF1-161D-4180-A9B5-3B121412056BQ42256888-CA1BC8C2-8A80-48E1-9513-DA8C1E0FC1E9Q44024646-CD348484-4E76-4A0B-9552-695A9A592ED0Q44483910-5331791E-A405-4A78-8E2B-CAD317FA7191Q45348994-BCA85F04-A0BA-45F4-9757-E26ECFE3F54E
P2860
Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO
description
im August 2007 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2007
@uk
name
Prostaglandin E2 is a key fact ...... imulatory capacity despite IDO
@en
Prostaglandin E2 is a key fact ...... imulatory capacity despite IDO
@nl
type
label
Prostaglandin E2 is a key fact ...... imulatory capacity despite IDO
@en
Prostaglandin E2 is a key fact ...... imulatory capacity despite IDO
@nl
prefLabel
Prostaglandin E2 is a key fact ...... imulatory capacity despite IDO
@en
Prostaglandin E2 is a key fact ...... imulatory capacity despite IDO
@nl
P2093
P356
P1476
Prostaglandin E2 is a key fact ...... imulatory capacity despite IDO
@en
P2093
Eva Singer
Marcus Groettrup
Paula I. Darley
Petra Krause
P304
P356
10.1189/JLB.0905519
P577
2007-08-14T00:00:00Z